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As a unique source of stem cells, there is a growing interest in amniotic epithelial (AE)
cells. Placenta is readily available; in fact, it is often discarded following delivery. As such,
it is without the ethical concerns of embryonic stem cells. Further advantages to AE
include that AE cells do not demonstrate tumorigenicity upon transplantation, and are gifted
with immunomodulatory and anti-inflammatory properties.Thus, AE cells have exceptional
features for use as cell-based therapies for liver disease.
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INTRODUCTION
Amniotic epithelial (AE) cell studies show promise in therapy in
liver disease in several ways: (A) AE cell therapy is an alternative
or bridge to solid organ transplantation as shown in both animal
models and clinical cases. (B) Transplanted cells can provide func-
tional liver support while the recipient’s liver regenerates in acute
liver failure patients and may provide a certain time as a bridge
until orthotopic liver transplantation (OLT). (C) They have valu-
able effect in substituting a missing enzyme function in metabolic
diseases with an aim of avoiding OLT. (D) Hepatocytes, embry-
onic stem cells, mesenchymal stromal cells, placental AE cells, and
induced pluripotent stem cells are the most capable cell types that
can be used in liver diseases. Thus, placental AE cell studies and its
therapy show promise in liver diseases (1–3). We aimed to review
current placental AE cell studies and its therapy in liver diseases.
HOW ANDWHY CAN AE CELLS BE USED?
Amniotic epithelial cells can be isolated from a full term placenta
following live birth. This readily available tissue is normally dis-
carded. Although any placenta is considered a useful source of
AE cells, AE cell isolations are typically obtained from cesarean
section deliveries due to sterility concerns. Perhaps at some future
date placental stem cells could be isolated from all term births
and cryopreserved in a cell bank for future use (3, 4). It is hard to
imagine religious or political opposition for such a benign source
of stem cells. A human placenta contains three different layers:
amnion, chorion, and decidua (Figure 1A). The amniotic layer
is composed of cuboidal and columnar cells and a deeper meso-
dermal layer composed of an upper compact acellular layer and
a lower fibroblast-containing layer. The amnion layer is derived
from pluripotent epiblast that gives rise to all three germ layers of
embryo. Amnion is derived at a time when the epiblast remains
pluripotent, and AE cells hold some of these characteristics. AE
cells can be isolated from a full term placenta. Placenta is a read-
ily available tissue and is generally discharged after delivery. It
provides a valuable source of pluripotent stem cells that cells are
plentiful and free from most ethical and religious concerns. There-
fore, in practice, placental stem cells can be isolated from all term
births and cryopreserved in a cell bank for future use (3, 4).
STEM CELL CHARACTERISTICS OF AE CELLS
Amniotic epithelial cells have stem cell molecular markers as OCT-
4, Nanog, SOX-2, and Rex-1. AE cells have some advantage over
embryonic stem cells; AE cells do not need feeder cell layers to pre-
serve OCT-4 and Nanog expression in their cultures (4, 5). Since
AE cells do not have telomerase reverse transcriptase, they show a
stable karyotype and do not develop any tumors. Other stem cells
have a common risk of teratoma development, when transplanted
(2, 5). AE cells are derived from neonatal tissue and therefore have
lesser DNA damage (6). Amnion does not express HLA class II
antigens; therefore, AE cells can bypass the immune system. AE
cells can inhibit inflammation and proliferation of T- and B-cells
in vitro by their secretions (7). AE cell transplantation in some
volunteers did not cause any immunological reactions. With their
non-tumorogenic characteristics (8–10), AE cells have beneficial
effects similar to embryonic stem cells but without their dangerous
side effects.
AE CELL ISOLATION AND DIFFERENTIATION METHODS
Amnion membrane can be peeled away from the chorion
(Figure 1B). It is the source of AE cells and amniotic mesenchy-
mal (AM) fibroblasts. We recommend our study group’s isolation
protocol (11). Briefly, amnion membrane is washed at least three
times to eliminate blood cells. Then trypsin can be applied to
release AE cells from AM fibroblasts and connective tissue. Then
cell suspension can be centrifuged to pellet AE cells and resus-
pended in standard. Cell viability is calculated by trypan blue stain
on hemocytometer. Our group’s proposed method can be used to
isolate 80–300 million cells from one term placenta (11), which is
a plentiful supply, indeed. Epidermal growth factor (EGF) is used
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FIGURE 1 | (A) Human placenta layers: amnion, chorion, and
decidua. Amniotic layer is composed of a single-celled epithelial
layer and a deeper mesodermal layer. Chorionic layer is composed
of a mesodermal layer and a trophoblast layer. (B) Isolation of
amnion membrane from placenta. The maternal side of placenta is
placed face down and a shallow X-shaped incision is made through
the center of the placenta. The thin, nearly transparent amnion
membrane is then peeled starting at the center of the cut and
progressing outward. (C) Morphology of amniotic epithelial cells in
culture (×40).
in AE cell cultures to promote their growth and differentiation
in vitro (Figure 1C) (4). Our study group also showed an efficient
method to differentiate AE cells to hepatocyte-like cells (2), which
expressed many hepatic marker genes. Since these hepatocyte-like
cells express CYP3A4 and CYP3A7, we can hypothesize that AE
cells are likely to differentiate along a pathway equivalent to human
fetal liver. Furthermore, the changing ratio of CYP3A4 to CYP3A7
in their growing period suggests that cells are developing mature
hepatocytes (12). Human AE cell transplantation to mice liver
also exhibited human hepatic genes expressions such as albumin,
cytochromes, and alpha-1 antitrypsin (2, 5).
WHY ARE AE CELLS PREFERRED OVER OTHER SOURCES OF
STEM CELLS?
Because, AE cells have stem cell characteristics with low immuno-
genicity, and anti-inflammatory possessions, they show exciting
potential in the regenerative medicine (Figure S1 in Supple-
mentary Material). AE cells exhibit hepatic gene expression and
functions close to mature hepatocytes level following their trans-
plantation into the liver of severely combined immunodeficiency
(SCID) mice, which prove their differentiation into hepatocyte-
like cells once engrafted in the parenchyma (5, 11). Recent
studies have shown that AE cells can engraft into the livers of
immunocompromised mouse of liver and improve any damage by
reducing hepatic fibrosis, inflammation, and apoptosis (2, 13). AE
cell transplantation successfully corrected lysosomal storage dis-
eases in clinics without any adverse effects (9, 10, 14). AE cell trans-
plantation can rescue a mouse model of intermediate maple syrup
urine disease (iMSUD) (1), which is a congenital disorder char-
acterized by deficiency of the branched-chain keto-acid dehydro-
genase (BCKDH) enzyme complex and elevated branched-chain
amino acids (BCAA) (15). In our group’s another study, iMSUD
model, mice were given multiple injections of AE cells directly
into liver parenchyma. Normally, untreated iMSUD mice can grow
sickly and all die prior to 27 days of age. IMSUD-treated mice could
display improved BCKDH enzyme activity, reduced BCAA, and
other relevant metabolites, they could gain weight as healthy wild
type littermates, and more than 70% of AE transplanted iMSUD
animals survived (1). Manuelpillai et al. transplanted human AE
cells to mice via tail vein on carbon tetrachloride (CCL4) model.
The AE treatment improved ALT levels, hepatic stellate cell acti-
vation, and hepatic fibrosis (13). Zhang et al. used intrasplenic
route to transplant AE cells in CCL4-treated mouse. They also
showed improvement on markers of ALT, apoptosis, and fibrosis
(16). Hodge et al. recently have showed that human AE treatment
suppresses markers of activation, proliferation, and fibrosis in
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human hepatic stellate cells in co-cultures. AE therapy also induces
apoptosis of hepatic stellate cells (17). Niemann–Pick disease is a
hereditary disorder of sphingomyelinase deficiency that leads to
excessive intracellular lipid accumulation and causes severe liver
damage and neuronal degeneration. Hong et al. used human AE
cells as a source of enzyme replacement in a mouse model of
Niemann–Pick disease. They transplanted half a million AE cells
every other week from 5 weeks of age. The treatment dramatically
prolonged the survival of the treatment group, and resulted in
improvement of tissue damage (18). Bembi et al. reported five type
B Niemann–Pick patients, in which AE cells supplied exogenous
sphingomyelinase, following the transplantation. AE transplanta-
tion normalized patients’ urinal sphingomyelin and phospholipid
levels (19).
BENEFITS OF AE CELLS
Amniotic epithelial cells are relatively easy to isolate and do not
require a complicated laboratory set up (4). Approximately 100
million cells per placenta can be isolated, and AE cells can grow
fast. Their smaller size, compared to hepatocytes brings techni-
cal advantage for their injection and engraftment. AE cells can
be cryopreserved long term. AE cells can have beneficial effects
of targeted cells and can transform clinically relevant cells. They
also secrete anti-inflammatory factors and are non-immunogenic.
Most likely, current umbilical cord blood stem cell guidelines
would be appropriate to use as a model for banking processes
for AE cells (20). We do not know whether hepatic differentiation
prior to transplantation is necessary for an effective method of
treatment. Since their safety has been clearly established, AE cells
with their potential effects continue to be a therapeutic hope in
liver diseases (Table S1 in Supplementary Material).
WHY ARE AE CELLS PREFERRED OVER OTHER SOURCES OF
STEM CELLS?
Currently, we need alternative cell sources to hepatocytes. Hepato-
cytes are very vulnerable cells and cannot survive mostly no more
than couple of weeks on the cultures. They are difficult to isolate
and their cryopreservation is not successful to keep their viability
high. Their larger size, compared to stem cells can cause technical
disadvantage for their injection and infusion. AE cells do not have
the disadvantages of hepatocytes. AE cells do not have any side
effects of other types of stem cells either. They are immunogenic
and are not tumorogenic in both undifferentiated and differen-
tiated stages. All other stem cell types have tumorigenicity risks
associated with their use in vivo. They do not cause acute rejection.
AE stem cells for cell transplantation are currently in preclinical or
early clinical stages. They are obviously the harmless alternate to
hepatocytes for therapies of liver diseases. AE type stem therapy is
a new hope substitute for hepatocytes in liver diseases.
IN CONCLUSION
In conclusion, current studies’ results suggest that AE cells isolated
from discarded placenta may be an abundant, non-controversial,
and safe source of stem cells for regenerative medicine. AE cell
transplantation can be an alternative therapy to OLT in the near
future to avoid the increasing amount of patient deaths due to
insufficient numbers of available livers and/or long organ wait
times. Cell transplantation has shown a great deal of promise,
and the progress made over the past several decades of preclin-
ical and clinical studies provides a growing amount of rationale
for its use to treat a variety of liver disorders. Currently, studies
with appropriate Neimann–Pick disease (18), acute liver failure
(21) and liver fibrosis (22, 23) models, and their correction by the
transplantation of human AE stem cells are motivating the move-
ment of banking of AE cells so that they can be used in the clinic
for transplantation to treat liver diseases.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at http://www.frontiersin.org/Journal/10.3389/fmed.2014.00048/
abstract
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